mProX™ Human NR1I2 Stable Cell Line

Product Information

Target Protein

NR1I2

Target Family

Vitamin D Receptor

Target Protein Species

Human

Host Cell Type

PC-3; CHO-K1; HEK293

Target Classification

Nuclear Receptor

Target Research Area

Cancer Research; Metabolic Research

Related Diseases

Cerebrotendinous Xanthomatosis; Biliary Tract Disease

Gene ID

8856

UniProt ID

O75469

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

The NR1I2 gene in humans encodes a protein known as the pregnane X receptor (PXR). PXR is a nuclear receptor whose main job is to detect foreign harmful chemicals and, in reaction, upregulate the expression of proteins that help the body detoxify and remove these poisons. PXR is a transcription factor that is a member of the nuclear receptor superfamily, which is distinguished by the presence of both a DNA-binding and ligand-binding domain. PXR, a transcriptional regulator of the cytochrome P450 gene CYP3A4, forms a heterodimer with the 9-cis retinoic acid receptor RXR by binding to the response element of the CYP3A4 promoter. Many substances that trigger CYP3A4 can activate it, such as rifampicin and dexamethasone. The customized NR1I2 stable cell line can be used in antibody discovery and development, potential drug candidate screening and signaling pathway researches.

Protocols

Please visit our protocols page.

Customer Reviews

chat Robert

I have used the NR1I2 KD cell line extensively in my studies, and it consistently delivered outstanding performance. Oct 17 2022

chat Verified Customer

chat Lisa

The performance of the NR1I2 cell line was consistent, and the company's support team was responsive and helpful throughout the process. Nov 12 2020

chat Verified Customer

FAQ

Any questions about our products? Please visit our frequently asked questions page.

Published Data

Fig.1 Functional characterization of PXR expressed in prostate cancer cell lines.

Expression of PXR was detected by RT-PCR. A positive control was a plasmid containing PXR. A negative control was the PCR reaction mixture without a template.

Ref: Chen, Yakun, et al. "Human pregnane X receptor and resistance to chemotherapy in prostate cancer." Cancer research 67.21 (2007): 10361-10367.

Pubmed: 17974979

DOI: 10.1158/0008-5472.CAN-06-4758

Research Highlights

This review addresses the use of NR1I2 and NR1I3 genetic polymorphism testing in clinical practice and gives an overview of pharmacogenetic investigations on these genes in a variety of therapeutic domains, including immunomodulation, cancer, and infectious diseases.
Mbatchi, Litaty Céphanoée, Jean-Paul Brouillet, and Alexandre Evrard. "Genetic variations of the xenoreceptors NR1I2 and NR1I3 and their effect on drug disposition and response variability." Pharmacogenomics 19.1 (2018): 61-77.
Pubmed: 29199543 DOI: 10.2217/pgs-2017-0121

These findings indicate that NR1I2 may be useful in predicting the toxicity of low-dose irinotecan and disclose for the first time its role in the pharmacogenetics of irinotecan.
Mbatchi, Litaty Céphanoée, et al. "Effect of single nucleotide polymorphisms in the xenobiotic-sensing receptors NR1I2 and NR1I3 on the pharmacokinetics and toxicity of irinotecan in colorectal cancer patients." Clinical pharmacokinetics 55 (2016): 1145-1157.
Pubmed: 27116457 DOI: 10.1007/s40262-016-0392-5